March 26, 2020 / 10:53 AM / 11 days ago

BRIEF-Relief Therapeutics Files With NeuroRx IND To FDA For Aviptadil To Treat Covid-19-Induced Respiratory Distress

March 26 (Reuters) - RELIEF THERAPEUTICS HOLDING SA :

* RELIEF THERAPEUTICS AND NEURORX, INC. FILE FDA IND FOR AVIPTADIL TO TREAT COVID-19-INDUCED RESPIRATORY DISTRESS

* FDA HAS GRANTED ORPHAN DRUG STATUS TO RELIEF THERAPEUTICS FOR DEVELOPMENT OF AVIPTADIL (VIP) IN ARDS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below